. The molecular pathology of ovarian carcinomas is heterogeneous and involves various putative precursor lesions and multiple pathways of development. Although very little is known regarding the molecular mechanisms involved in the biochemical alterations of cell signaling, most of them lead to abnormal growth which depends on altered stimulation by growth factor receptor-cell signaling pathways. Stimuli follow different pathways, but a substantial number of them converge in the mammalian target of rapamycin (mTOR) which plays a central role in cancerogenesis and, as we have recently shown, its key pathway components have been implicated in the development of endometriosis [2, 3] . mTOR is a conserved seronine/threonine kinase which functions by integrating extracellular signals (growth factors and hormones). mTOR enhances translation initiation in part by phosphorylating a group of its major targets, such as: transcription factor eIF4E (mRNA cap-binding protein) which is a known potent oncogene, and selected tumor suppressor genes, like: 4E-BP1 (the so called inhibitory 4E-binding protein) considered a hallmark of cell signaling in ovarian cancer [4] , and ribosomal protein S6 kinases (e.g. oncogene S6K1) that co-operate to regulate gene expression and translation processes [2] .
S6K1 has also been shown to repress the phosphatidylinositol 3-kinase (PI3K) related pathways. PI3K oncogene is a heterodimer that is composed of a p85 regulatory and a p110 catalytic subunit (coded for by the PIK3CA), and its aberrantly high activity has been implicated in cell transformation and tumor progression in a variety of human cancers [5] . PI3K converts PIP2 to PIP3 (phosphatidylinositol-3, 4,5-triphosphate), which is actively opposed by its phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome ten) tumor suppressor of which loss of function has been found in many advanced human cancers [6] . PIP3 recruits one of the most potent oncogenes AKT [5] to the membrane where it is activated by phosphorylation. Once activated, AKT phosphorylates a multitude of proteins, with the net result of increased cellular survival, proliferation, growth and metabolism. Specifically, phosphorylation of mTOR by AKT occurs through inactivation of the tuberous sclerosis complex -heterodimer consisting of unphosphorylated tumor suppressors TSC1 and TSC2 [7] . The complex acts as a GTPase-activating protein (GAP), inhibiting the small G-protein Rheb (Ras homolog enriched in brain), an oncogene of which expression is elevated in many tumor cells [8] .
TSC1, TSC2 and Rheb also contribute to the activation of mTOR after losing such tumor suppressors as: NF1 (neurofibromatosis 1), LKB1 (also known as serine-threonine kinase 11) or p53 [2] . NF1 also encodes a GAP for Rat Sarcoma (RAS), of which mutations result in hyperactivation of the protein and are among the most frequent alterations in human cancers. It has also been found that prolonged activation of k-ras can occur in tumors by mechanisms that do not involve mutations [9] .
P53, which plays a pivotal role in safeguarding the integrity of the genome, harbors mutations in more than 50% of human cancers of all tissue origins [10] and is also a central signal integrator of stress, such as DNA damage or hypoxia. When activated, it initiates cellular tumor suppression programs such as apoptosis, cell cycle arrest or autophagy.
Autophagy was recently established as a novel tumor suppression mechanism which leads to lysosomal degradation of cytoplasmic components. Genetic evidence shows that compromised autophagy plays a causal role in tumorigenesis. Specifically, decreased expression of BECN1 (beclin-1) is associated with human breast cancer, ovarian and prostate cancer [11] . Moreover, autophagy is negatively regulated by mTOR which is a central protein that integrates signals from nutrients and growth factors [12] .
Our aim was to profile the expression status of the aforementioned key tumor suppressor genes and oncogenes that could be functionally related to the mTOR pathway [13] in ovarian cancer. We also attempted to show that the low-density microfluidic gene chip is an effective technique to examine the expression of different genes in such a heterogeneous tissue as the ovary.
Material and methods Material and methods Material and methods Material and methods Material and methods
Tissue samples (n = 93) from patients with invasive ovarian cancer, benign ovarian cysts and normal ovaries were collected during surgery performed in the Department of Gynecology of the Medical University of Bialystok, the Department of Gynecologic Oncology of the Medical University of Gdansk, and the Department of Gynecology and Gynecologic Oncology of the Military Institute of Health Sciences in Warsaw. The operations were performed in 2006 and 2009. We initially collected samples from a total of 80 patients diagnosed with an ovarian malignancy (n = 53) on frozen section who underwent full surgical staging or tumor debulking as clinically indicated. A piece of each collected tissue was divided into two halves and placed separately in buffered formalin for histopathological studies and RNA later (Sigma Aldrich, Poland) for molecular analysis. The latter was stored for 24 hours at 4°C and then tissues were transferred and stored at -80°C. Two opposite margins were checked by means of histology in all cases and proven to consist of cancer tissue only (> 90% www.fhc.viamedica.pl ovarian cysts (endometrial and simple), initially collected during laparoscopy from 45 patients, as well as normal ovaries removed from 19 patients during total hysterectomy performed because of fibroids during laparotomy, were chosen as controls. The study was approved by the Institutional Review Board (IRB) and the patients gave their informed consent before inclusion in the study. The RNA isolation was performed using a total RNA isolation kit from Macherey-Nagel (Duren, Germany) according to the manufacturer's protocol. RNA concentration and quality was determined using a NanoDrop spectrophotometer (Kisker, Steinfurt, Germany) and the Agilent Bioanalyzer 2100 (Agilent Technologies, Perlan, Poland).
Total RNA was subsequently converted to single stranded cDNA and loaded into the custom-designed 16 gene expression assay (three replicates per assay) of the TaqMan real-time PCR microfluidic gene array system (Applied Biosystems, Warsaw, Poland). The assay Ids, including house--keeping gene, and detailed procedures (including thermal cycle PCR conditions) were exactly the same as those described in our most recent publication [3] .
Gene expression values (RQ-relative quantity) were calculated based on the DDC t method, where one sample was designated as the calibrator, through which all other samples were analyzed [14] .
Immunohistochemistry. Immunohistochemistry. Immunohistochemistry. Immunohistochemistry. Immunohistochemistry. For the immunohistochemical studies, a representative section from the resected specimen was selected. Four-micrometer-thick sections were deparaffinized and dehydratated. Endogenous peroxidase activity was blocked by Peroxidase Blocking Reagent for five minutes at room temperature. For antigenic recovery, the material was immersed in citrate buffer (pH = 6) and placed in a microwave oven for 20 minutes. After rinsing in PBS buffer pH = 7.4 (P53, BECN1) and Tris (PTEN, PIK3CA), the sections were incubated with studied primary antibodies for 24 hours at 4°C, or ten minutes at room temperature. PTEN (anti-human/mouse PTEN), p53 (mouse monoclonal antibody), PIK3CA (rabbit anti-PIK 3CA) and BECN1 (mouse monoclonal antibody) were assessed using monoclonal mouse antibodies, namely: anti-human PTEN from R&D Systems (clone 217702) which was diluted 1:40 in Tris buffer pH = 7.4; p53 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, clone BP53.12) diluted 1:100 in blocking serum, PIK3CA (Sigma, HPA009985) diluted 1:50 in Tris buffer pH7.4 and BECN1 (Santa Cruz Biotechnology, clone BP53.12) diluted 1:100 in blocking serum.
Sections were then incubated with biotinylated secondary antibody at room temperature for 30 minutes. Afterwards, sections were incubated with ABC solution (Santa Cruz Biotechnology, BECN, P53 and PIK3CA) and R&D Systems Cell and Tissue Staining Kits (PTEN), at room temperature for 30 minutes, followed by diaminobenzidine tetrachloride solution at room temperature for ten minutes, and counterstained in Mayer's hematoxylin. Sections were subsequently dehydrated, transferred to xylene and eventually mounted in a resinous mountant. The expression of studied proteins was evaluated with the use of light microscopy (Olympus CX21). Appropriate immunohistochemical controls, positive and negative, were carried out.
For statistical analysis, the Kruskal-Wallis nonparametric test was used to compare RQ values of three groups together (ovarian cancer vs. benign ovarian cysts vs. healthy ovaries). Wilcoxon rank-sum test was then used for the comparison of RQ values between ovarian cancer vs. benign ovarian cysts, ovarian cancer vs. healthy ovaries and benign ovarian cysts vs. healthy ovaries. The significance level was equal to 0.05. The statistical analysis was performed using a SAS STAT package.
R R R R Results esults esults esults esults
Patient clinico-pathological characteristics are presented in Table 1 . Detailed RQ and p values in three main study groups are presented in Table 2 . Because our control group consisted of two relatively different subgroups of tissues (normal ovaries and benign cysts), we decided to divide our study group into three groups and then perform statistical analysis on them. We succeeded in obtaining adequate RNA only from 53 patients with ovarian cancer, 29 with benign ovarian cysts and 11 healthy ovaries. These comprised our T T T T www.fhc.viamedica.pl main study group and were used for further molecular analysis. By the use of Kruskal-Wallis, we could compare three groups together. We found significant differences for most of the studied genes, except for mTOR (p = 0.86), KRAS (p = 0.59) and AKT1 (p = 0.16). Then we attempted to compare, by the use of Wilcoxon rank-sum test, whether differences existed as to the RQ values between combinations of subgroups, i.e. ovarian cancer vs. healthy ovaries, ovarian cancer vs. benign cysts and healthy ovaries vs. benign cysts. We found that only for four genes, namely PTEN, TP53, PIK3CA and BECN1, were there significant differences between ovarian cancer and each of the two control groups ( Table 2 ). The median RQ values of the four genes were significantly lower in patients with ovarian cancer compared to two control groups. No differences were found between normal ovaries and benign cysts for three of the four genes i.e. TP53 (p = 0.55), PIK3CA (p = 0.98) and BECN1 (p = 0.65). The only exception, PTEN, exerted the highest median gene expression in normal ovaries which was significantly higher than in benign cysts (p = 0.003) and ovarian cancer subgroup (p = 0.0019), which showed the lowest median concentration. Analysis carried out with a group of malignant tumors (n = 53) showed no statistically significant correlation between all 15 tested genes and age, grade (I, II vs. III) or clinical stage (I, II vs. III, IV).
We also decided to study differences in the median RQ values of all genes between two histological types i.e. serous and endometrial. The number of other types was too small for statistical analysis. We found that the differences were significant for two out of 15 studied genes, namely BECN1 (p = 0.008) and TSC2 (p = 0.034). The expression of both genes was decreased in serous ovarian cancer: respective median (minimum-maximum) RQ values for BECN1 and TSC2 were: 0.36 (0.09-6.56) and 0.32 (0.08-15. In order to confirm protein expression of genes that were differentially regulated in our study, we studied their immunolocalization in selected cases of four main histological types (serous, endometrioid, clear cell and mucinous) of ovarian cancer. Among studied tissue sections, immunoreactivity for PTEN (nuclear and cytoplasmic) was observed only in clear cell (15% of cells) and mucinous types in about 5% (Figures 1A and 1B, respectively) whereas neither expression was observed in studied serous nor endometrioid slides. TP53 protein localization was nuclear and we could observe strong reaction in 50-60% of endometrioid ( Figure 1C ) and 80-90% of clear cell types ( Figure 1D) . Very little or no reaction was observed in the serous or mucinous types studied.
PIK3CA exhibited very strong immunohistochemical reaction in all histological types studied and average staining was about 80% in serous, endometrioid and mucinous types ( Figures 1E, 1F, 1G , respectively), whereas we could observe that only 30% of clear cell cancer cells showed, typical for all types, cytoplasmic reaction ( Figure 1H ).
In the case of BECN1, we observed a weak cytoplasmic reaction in virtually all histological types studied. In the cases of serous cancer sections, the positive reaction was observed in only 5% of cells ( Figure 1I ). Endometrioid cancer cells exhibited 10--12% positive reactions ( Figure 1J ). Despite the fact that we did not observe a positive BECN1 reaction in clear cell or mucinous cancer cells, in every histological type we could see characteristic vascular, specifically endothelial, positive reactions of this protein (see arrow in Figure 1I ).
Discussion
Discussion Discussion Discussion Discussion A decrease in PTEN expression, which may lead to loss of its function, is more frequent than can be explained by structural genomic changes alone, since epigenetic phenomena, such as hypermethylation of DNA, represent major restrictions to the transcriptional process. PTEN expression can be lost or greatly reduced in some tumors without any mutation in the coding sequence of the gene in cancers of breast, prostate, non-small cell lung, as well as ovarian cancer [15] .
Schondorf et al. showed that expression of PTEN is not altered in the progression of ovarian carcinoma, which suggests that in ovarian cancer PTEN does not play a major role in disease progression [16] . Another study found that the level of PTEN mRNA expression was negatively correlated with clinicopathological staging of ovarian cancer, whereas it was positively correlated with histological differentiation. It has also been shown that mRNA expression level of PTEN gene in ovarian endometrioid cancer was significantly lower than that in ovarian serous cancer [17] . In our study, we were unable to show differences as to the expression of PTEN between those two histological types of cancer. This was possibly due to an insufficient number of samples (eight endometrioid vs. 34 serous). The decrease of autophagic capacity, related to lower beclin-1 expression, has been recently shown by immunohistochemical studies in epithelial ovarian cancer [18] . It has been found that BECN1 gene levels were significantly higher in benign and borderline ovarian tumors than in epithelial ovarian carcinoma. In another study, higher expressions of Beclin-1 protein were found in normal and benign ova- www.fhc.viamedica.pl rian neoplasia tissues; the expressions were reduced in the borderline lesion tissue and the lowest level of expressions could be detected in the ovarian carcinoma tissue [19] . Although two of these studies were published in Chinese, making it difficult to describe methodology, we believe that the immunostaining of Beclin-1 was prevalent in ovarian cancer specimens. In our study, we for the first time confirmed that the median mRNA expression level is lower in malignant compared to non-malignant lesions of the ovaries, but the protein immunolocalization is relatively scarce and weak. Decreased levels of TP53 are not surprising since inactivation of this gene appears to be an early step 
